Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2023 21:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Pricing of $9.6 Million Public Offering

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
September 28, 2023 08:00 ET | Source: Vaccinex, Inc.

Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select...
June 01, 2023 08:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET

ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
May 15, 2023 16:45 ET | Source: Vaccinex, Inc.

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...
April 12, 2023 08:00 ET | Source: Vaccinex, Inc.

Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells

GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New...
March 23, 2023 08:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference

ROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, “Vaccinex”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
March 21, 2023 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade ...
March 09, 2023 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study...
November 10, 2022 09:00 ET | Source: Vaccinex, Inc.

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

ROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
August 15, 2022 08:10 ET | Source: Vaccinex, Inc.

Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs

Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in...